Status:
UNKNOWN
The Potential Biomark of Serious Psychosis:a Prospective,Case-controled Study
Lead Sponsor:
Central South University
Conditions:
Other Immunological States or Disorders
Eligibility:
All Genders
18-65 years
Brief Summary
Patients suffer from Serious Psychosis may have variation in immunological factors,BDNF and MRI.
Detailed Description
Patients suffer from Schizophrenia and Mood Disorders may have variation in immunological factors(TNF-α,IL-2,IL-6,IL-10,etc),BDNF and Brain MRI.
Eligibility Criteria
Inclusion
- Diagnosis with Schizophrenia , Bipolar Disorder or Major Depression by DSM-5
Exclusion
- Unstable physical conditions
Key Trial Info
Start Date :
August 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02202460
Start Date
August 1 2014
End Date
December 1 2020
Last Update
July 29 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mental Health Institute of 2nd Xiangya Hospital,CSU
Changsha, Hunan, China, 410011